Patents by Inventor Yarlagadda S. Babu

Yarlagadda S. Babu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS
    Publication number: 20240408096
    Abstract: Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit from ALK2 kinase inhibition (e.g., Fibrodysplasia Ossificans Progressiva and cancer).
    Type: Application
    Filed: December 20, 2021
    Publication date: December 12, 2024
    Inventors: Yarlagadda S. Babu, William P. Sheridan
  • Human plasma kallikrein inhibitors
    Patent number: 12162838
    Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: December 10, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
  • IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE
    Publication number: 20240376117
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: April 26, 2024
    Publication date: November 14, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satisha Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
  • Antiviral treatments
    Patent number: 12121503
    Abstract: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: October 22, 2024
    Assignee: BIOCRYST PHARMACEUTICALS, INC.
    Inventors: Yarlagadda S Babu, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
  • Human plasma kallikrein inhibitors
    Patent number: 12116346
    Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: October 15, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
  • SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS
    Publication number: 20240294494
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: January 8, 2024
    Publication date: September 5, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE
    Publication number: 20240270750
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: May 24, 2022
    Publication date: August 15, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Wei Lv, Peng-Cheng Lu, Andrew E. Spaulding, Krishnan Raman
  • Imidazole-containing inhibitors of ALK2 kinase
    Patent number: 12054492
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: August 6, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
  • Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
    Patent number: 12043610
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: July 23, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5
    Publication number: 20240239752
    Abstract: Disclosed are compounds of formulae (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity, such as Netherton Syndrome.
    Type: Application
    Filed: April 14, 2022
    Publication date: July 18, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Zhao Dang, Krishnan Raman
  • HUMAN PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240150296
    Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Application
    Filed: April 18, 2023
    Publication date: May 9, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
  • HUMAN PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240150295
    Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Application
    Filed: April 18, 2023
    Publication date: May 9, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
  • Methods and compositions for treatment of Zika virus infection
    Patent number: 11975003
    Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of viral RNA polymerase. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or suppression of a Zika virus infection or a disease or condition associated with a Zika virus infection.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: May 7, 2024
    Assignee: BIOCRYST PHARMACEUTICALS, INC.
    Inventors: Yarlagadda S. Babu, Pravin L Kotian, Shanta Bantia
  • CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR
    Publication number: 20240109844
    Abstract: Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.
    Type: Application
    Filed: March 10, 2023
    Publication date: April 4, 2024
    Inventors: Yahya El-Kattan, Yarlagadda S. Babu
  • METHODS OF TREATING HEMATOLOGIC CANCERS
    Publication number: 20240100055
    Abstract: The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.
    Type: Application
    Filed: November 1, 2023
    Publication date: March 28, 2024
    Inventors: Shanta BANTIA, Philip BREITFELD, Yarlagadda S. BABU
  • Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
    Patent number: 11866418
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: January 9, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Human plasma kallikrein inhibitors
    Patent number: 11807605
    Abstract: Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: November 7, 2023
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Lakshminarayana Vogeti
  • IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE
    Publication number: 20230271975
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: February 13, 2023
    Publication date: August 31, 2023
    Inventors: PRAVIN L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
  • Human plasma kallikrein inhibitors
    Patent number: 11708333
    Abstract: Disclosed are compounds of formula I: as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: July 25, 2023
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Venkat R. Chintareddy, V. Satish Kumar, Weihe Zhang
  • Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
    Patent number: 11708347
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: July 25, 2023
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman